BCT

POTOMAC BANCSHARES, INC. REPORTS 2023 FOURTH QUARTER AND FULL YEAR RESULTS

Retrieved on: 
Thursday, February 1, 2024
PPP, ROA, Growth, Pressure, FDIC, Government, ROE, AFS, Investment, OTC, The Company, Total, Bank, Insurance, BCT, Movement, Self storage

In the fourth quarter, we hired a Director of Government Lending to build this unit and expand our government lending strategy.

Key Points: 
  • In the fourth quarter, we hired a Director of Government Lending to build this unit and expand our government lending strategy.
  • Excluding this loss, the earnings for the fourth quarter of 2023 would have been $1.830 million or $0.44 per share.
  • Net unrealized losses in the AFS portfolio were $8.7 million as of Q4 2023 and $11.9 million as of Q3 2023.
  • The allowance for credit losses was 1.02% of total loans outstanding as of Q4 2023 and 1.04% as of Q3 2023.

RTX completes milestones on DARPA Blackjack Program with four Blue Canyon Technologies satellites

Retrieved on: 
Tuesday, January 30, 2024
Orbit, Growth, LEO, RTX, DARPA, BCT, Communications satellite

LAFAYETTE, Colo., Jan. 30, 2024 /PRNewswire/ -- RTX's (NYSE: RTX) small-satellite manufacturer and mission services provider, Blue Canyon Technologies (BCT), announced today the satellites supporting the Defense Advanced Research Projects Agency (DARPA) Blackjack program have completed critical milestones activities.

Key Points: 
  • LAFAYETTE, Colo., Jan. 30, 2024 /PRNewswire/ -- RTX's (NYSE: RTX) small-satellite manufacturer and mission services provider, Blue Canyon Technologies (BCT), announced today the satellites supporting the Defense Advanced Research Projects Agency (DARPA) Blackjack program have completed critical milestones activities.
  • National security space assets, critical to U.S. warfighting capabilities, traditionally reside in a geosynchronous orbit to deliver persistent overhead access to any point on the globe.
  • To potentially replace these large systems, the Blackjack program seeks to establish an equally effective network in low-Earth orbit using a constellation of four connected satellites.
  • "The Blackjack program is a perfect example of how RTX and Blue Canyon Technologies are working to solve the hardest problems in aerospace and defense," said Chris Winslett, general manager for Blue Canyon Technologies.

POTOMAC BANCSHARES, INC. DECLARES QUARTERLY DIVIDEND

Retrieved on: 
Friday, January 19, 2024
Bank, BCT, OTC, The Company

CHARLES TOWN, W.Va., Jan. 19, 2024 /PRNewswire/ -- (OTC:PTBS) – The Board of Directors of Potomac Bancshares, Inc. (the "Company"), the one bank holding company for Bank of Charles Town (BCT), declared at their January Board meeting a quarterly dividend of $0.10 per share.

Key Points: 
  • CHARLES TOWN, W.Va., Jan. 19, 2024 /PRNewswire/ -- (OTC:PTBS) – The Board of Directors of Potomac Bancshares, Inc. (the "Company"), the one bank holding company for Bank of Charles Town (BCT), declared at their January Board meeting a quarterly dividend of $0.10 per share.
  • The dividend is for all shareholders of record on February 2, 2024, and will be paid on February 9, 2024.

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

Retrieved on: 
Thursday, January 4, 2024
MRI, Neoplasm, Breast cancer, Woman, BCT, Eye, Therapy, CNS, TSX, Patient, Central nervous system, Magnetic resonance imaging, Exophthalmos, Medical imaging

The patient had metastatic breast cancer behind her eye, causing proptosis (eye-bulging) and significant pain that were both markedly reduced with BriaCell’s treatment.

Key Points: 
  • The patient had metastatic breast cancer behind her eye, causing proptosis (eye-bulging) and significant pain that were both markedly reduced with BriaCell’s treatment.
  • We observed significant tumor reduction along with significant eye pain reduction after only 3 cycles of treatment with the Bria-IMT™ combination regimen.
  • The Bria-IMT™ regimen has been very well tolerated and the patient remains on treatment,” stated Dr. William V. Williams, BriaCell’s President and CEO.
  • The Bria-IMT™ combination regimen is currently undergoing a pivotal Phase 3 study in advanced breast cancer.

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

Retrieved on: 
Thursday, December 28, 2023
Breast cancer, BCT, Therapy, Cancer, CPI, CNS, TSX, Patient, Central nervous system, History, Pharmaceutical industry

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 28, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report marked 71% intracranial objective response rate (iORR) in advanced breast cancer patients suffering from central nervous system (CNS) metastases and treated with BriaCell’s Bria-IMT™ regimen.

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, Dec. 28, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report marked 71% intracranial objective response rate (iORR) in advanced breast cancer patients suffering from central nervous system (CNS) metastases and treated with BriaCell’s Bria-IMT™ regimen.
  • iORR is defined as the percentage of patients who achieve either a complete response (complete disappearance) or partial response (volume reduction of 30% or more) in intracranial tumors.
  • Breast cancer metastasis (spread of the cancer) to the CNS presents a significant clinical challenge, often leading to poor prognosis and early death.
  • BriaCell has recently conducted a retrospective analysis in breast cancer patients with CNS metastases enrolled across both its Bria-IMT™ monotherapy and combination therapy with CPI studies and found remarkable clinical responses.

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

Retrieved on: 
Wednesday, December 20, 2023
Immunotherapy, Rated R, Survival, Efficacy, Breast cancer, Spacecraft, ILD, Kaplan–Meier estimator, BCT, Complex conjugate, Literature, Therapy, MBC, Toxicity, Antibody-drug conjugate, TSX, Patient, PFS, ADC, Pharmaceutical industry

“We are excited with our findings of unprecedented survival and clinical benefit in very difficult-to-treat patients who failed ADCs and view our findings as a significant clinical breakthrough in the field of cancer therapy.

Key Points: 
  • “We are excited with our findings of unprecedented survival and clinical benefit in very difficult-to-treat patients who failed ADCs and view our findings as a significant clinical breakthrough in the field of cancer therapy.
  • Kaplan-Meier analysis showed median overall survival (OS) that was up to twice that reported in the literature, with some patients recording survival of over a year.
  • Progression free survival (PFS) was similar or better than that of the patients’ prior therapy in 40% of patients, highlighting clinical benefit and tolerability of the Bria-IMT™ regimen.
  • 17 of 23 patients remain alive as of today, suggesting efficacy, tolerability, and survival benefit of BriaCell’s Bria-IMT™ regimen.

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

Retrieved on: 
Wednesday, December 6, 2023
Survival, Probability, Allogenic succession, Kaplan–Meier estimator, BCT, NLR, Cancer, Therapy, CPI, University, Lymphocyte, Toxicity, TSX, Patient, Pharmaceutical industry

32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.

Key Points: 
  • 32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.
  • PHILADELPHIA and VANCOUVER, British Columbia, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is thrilled to announce continued outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated Bria-IMT™ in combination with an immune check point inhibitor (CPI).
  • The data is being revealed at the 2023 San Antonio Breast Cancer Symposium® held at Henry B. Gonzalez Convention Center, San Antonio, TX.
  • In summary, the consistent topline survival and clinical benefits support BriaCell’s hypothesis of additive and/or synergistic effects of immune check point inhibitors with Bria-IMT™ and support the ongoing pivotal study of our combination regimen in the treatment of advanced metastatic breast cancer.

BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

Retrieved on: 
Wednesday, December 6, 2023
Patient, Associate, Immunotherapy, Survival, CEA, CD8, Immune system, Breast cancer, BCT, Antibody, Clinical Radiology, Therapy, Cancer, University, Neoplasm, Lymphocyte, Poster, TSX, Cell, CA15-3, Vaccine

Today’s posters highlight the activation of cancer fighting immune cells by the Bria-IMT™ combination regimen that was identified using leading-edge technologies.

Key Points: 
  • Today’s posters highlight the activation of cancer fighting immune cells by the Bria-IMT™ combination regimen that was identified using leading-edge technologies.
  • “We were able to see that the Bria-IMT™ combination regimen treatment can activate cancer-fighting T cells to infiltrate some breast cancer tumors.
  • This indicates activation of these cells and their invasion into the tumors potentially leading to destruction of cancer cells.
  • We observed favorable changes in tumor markers (CEA and CA15-3), Circulating Tumor Cells, and Cancer Associated Macrophage Like cells suggesting activation of tumor fighting cells.

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

Retrieved on: 
Thursday, November 30, 2023
Survival, HER2, Breast cancer, BCT, Disease, Brain, Cancer, Eye, Therapy, Skull, University, Sternum, Neoplasm, Observation, Spine, Face, TSX, Patient, Central nervous system, Pelvis, Exophthalmos, Pharmaceutical industry

After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye.

Key Points: 
  • After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye.
  • BriaCell’s clinical team reported a patient with extensive metastatic breast cancer who had failed all available therapies.
  • “We were excited to offer her the latest treatments and thrilled to share in her success and joy.”
    The noted responder, a post-menopausal metastatic breast cancer patient (the “Remarkable Responder”), experienced a remarkable improvement of proptosis caused by breast cancer tumors behind the eye, resulting in significant pain reduction in the ocular region.
  • BriaCell had previously reported a similar case of a remarkable response with 100% resolution of an eye-bulging orbital tumor ( release here ).

The Ultimate Baseus Christmas Gift Guide for Any Gadget Lover

Retrieved on: 
Tuesday, December 19, 2023
Coupon, Mini, IPhone, Rain, BCT, Electronics, ANC, Android, Gallium nitride, IPX6, Seamless, Safety, MagSafe, Life

LOS ANGELES, Dec. 19, 2023 /PRNewswire/ -- Baseus Technology, the leading global consumer electronics brand, has prepared an Ultimate Baseus Christmas Gift Guide for Any Gadget Lover.

Key Points: 
  • LOS ANGELES, Dec. 19, 2023 /PRNewswire/ -- Baseus Technology, the leading global consumer electronics brand, has prepared an Ultimate Baseus Christmas Gift Guide for Any Gadget Lover.
  • When it comes to finding a technology-forward gift for someone on your list, the Baseus Tech Gadget collection shines as a beacon of innovation.
  • This magnificent power bank is during the 30% off promotion on Amazon , come and get one for someone on your gift list.
  • This holiday season, give the gift of innovation and convenience with Baseus tech products.